Investor News & Events

Press Releases

June 20, 2025

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

June 17, 2025

Press release: Sanofi successfully prices €1.5 billion bond issue

June 15, 2025

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Read the Press Release

See more press releases

Upcoming Events

31Jul

2025

Second Quarter 2025

Second quarter 2025 results will be reviewed by management during a live audio webcast with the financial community on July 31, 2025. The presentation will be followed by a Q&A session.

15:00 - 16:30 CET (9:00am – 10:30am EDT)

Quarterly results

24Oct

2025

Third Quarter 2025

Third quarter 2025 results will be reviewed by management during a live audio webcast with the financial community on October 24, 2025. The presentation will be followed by a Q&A session.

14:30 - 16:00 CET (8:30am – 10am EDT)

Quarterly results

See all upcoming events

Past Events

24Apr

2025

First quarter 2025

First quarter 2025 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.

Quarterly results

Discover more

30Jan

2025

Fourth Quarter & Full Year 2024 Results

Fourth quarter and full year 2024 results were reviewed by management during a live audio webcast with the financial community on January 30, 2025. The presentation was followed by a Q&A session.

15:00 - 16:30 CET (9:00am – 10:30am EST)

Quarterly results

Discover more

25Oct

2024

Third quarter 2024 results

Third quarter 2024 results were reviewed by management during a conference call with the financial community. The presentation was followed by a Q&A session.

14:00 - 15:30 CET (8:00am – 9:30am EST)

Quarterly results

Discover more